Curcumin mediates glutathione depletion via metal–organic framework nanocarriers to enhance cisplatin chemosensitivity on esophageal cancer
Source abstract
Abstract
Cisplatin (CDDP) is the primary drug used in the initial treatment of esophageal cancer (EC). However, its side effects and resistance can limit its effectiveness in clinical therapy. Curcumin (Cur)-mediated glutathione (GSH) depletion can reverse resistance, enhance the chemosensitivity of CDDP, and further improve the efficacy of platinum-containing chemotherapy in the treatment of esophageal cancer. However, it is also faced with problems of poor water solubility and low bioavailability in vivo, which severely hinders cancer treatments. In order to address these issues, we developed a novel nanotherapeutic system called CDCZA, combining Cur/CDDP/Cu/ZIF8@Au to enhance chemotherapy through GSH depletion and chemodynamic therapy through self-produced H 2 O 2 . Cu and CDDP were precisely co-loaded into Cu/ZIF8 nanoparticles using a one-pot method, then ultra-small gold nanoparticles mimicking glucose oxidase (Au nanoparticles) were embedded in the outer shell to create the CDCZA nano system. The released Cur could notably decrease intracellular GSH content and thus improve the chemosensitivity of CDDP, resulting in severe cellular apoptosis. And the Au nanoparticles effectively enabled chemodynamic therapy enhancement by accelerating the depletion of β-D-glucose into H 2 O 2 . As a result, the CDCZA nanoparticles showed increased tumor accumulation and improved antitumor effectiveness in a model of EC. Taken together, this work provides a new idea for the clinical design of efficient treatment reagents for EC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Metal-Organic Frameworks: Synthesis and Applications · Sulfur Compounds in Biology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (18)
Show source-provided references
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Ca-Cancer. J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21492.10.3322/caac.21492 ↗
2. di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154:421–36. https://doi.org/10.1053/j.gastro.2017.07.041.10.1053/j.gastro.2017.07.041 ↗
3. McCormack VA, Menya D, Munishi MO, Dzamalala C, Gasmelseed N, Leon Roux M, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific ex-posures to known and putative risk factors. Int J Cancer. 2017;140:259–71. https://doi.org/10.1002/ijc.30292.10.1002/ijc.30292 ↗
4. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83. https://doi.org/10.1038/onc.2011.384.10.1038/onc.2011.384 ↗
5. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257. https://doi.org/10.1038/cddis.2013.428.10.1038/cddis.2013.428 ↗
6. Zheng M, Liu S, Guan X, Xie Z. One-step synthesis of nanoscale zeolitic imidazolate frameworks with high curcumin loading for treatment of cervical cancer. ACS Appl Mater Inter. 2015;7:22181–7. https://doi.org/10.1021/acsami.5b04315.10.1021/acsami.5b04315 ↗
7. Bahrami A, Atkin SL, Majeed M, Sahebkar A. Effects of curcumin on hypoxia-inducible factor as a new therapeutic target. Pharmacol Res. 2018;137:159–69. https://doi.org/10.1016/j.phrs.2018.10.009.10.1016/j.phrs.2018.10.009 ↗
8. Tang Z, Liu Y, He M, Bu W. Tumor microenvironment-mediated Fenton and Fenton-like reactions. Angew Chem Int Ed. 2019;58:946–56. https://doi.org/10.1002/ange.201805664.10.1002/ange.201805664 ↗
9. Gao S, Jin Y, Ge K, Li Z, Liu H, Dai X, et al. Self-supply of O2 and H2O2 by a nanocatalytic medicine to enhance combined chemo/chemodynamic therapy. Adv Sci. 2019;6:1902137. https://doi.org/10.1002/advs.201902137.10.1002/advs.201902137 ↗
10. Lin LS, Huang T, Song J, Ou XY, Wang Z, Deng H, et al. Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy. J Am Chem Soc. 2019;141:9937–45. https://doi.org/10.1021/jacs.9b03457.10.1021/jacs.9b03457 ↗
11. Gao S, Lin H, Zhang H, Yao H, Chen Y, Shi J. Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv Sci. 2019;6:1801733. https://doi.org/10.1002/advs.201801733.10.1002/advs.201801733 ↗
12. Liu C, Xing J, Akakuru OU, Luo L, Sun S, Zou R, et al. Nanozymes-engineered metal-organic frameworks for catalytic cascades-enhanced synergistic cancer therapy. Nano Lett. 2019;19:5674–82. https://doi.org/10.1021/acs.nanolett.9b02253.10.1021/acs.nanolett.9b02253 ↗
13. Xie Z, Liang S, Cai X, Ding B, Huang S, Hou Z, et al. O2-Cu/ZIF-8@Ce6/ZIF-8@F127 Composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy. ACS Appl Mater Inter. 2019;11:11671–80. https://doi.org/10.1021/acsami.9b10685.10.1021/acsami.9b10685 ↗
14. Schejn A, Aboulaich A, Balan L, Falk V, Lalevée J, Medjahdi G, et al. Cu2+-doped zeolitic imidazolate frameworks (ZIF-8): efficient and stable catalysts for cycloadditions and condensation reactions. Catal Sci Technol. 2015;5:1829–39. https://doi.org/10.1039/C4CY01505C.10.1039/C4CY01505C ↗
15. Park KS, Ni Z, Cote AP, Choi JY, Huang R, Uribe-Romo FJ, et al. Exceptional chemical and thermal stability of zeolitic imidazolate frameworks. Proc Natl Acad Sci USA. 2006;103:10186–91. https://doi.org/10.1073/pnas.060243910316.10.1073/pnas.060243910316 ↗
16. Xu Y, Han X, Li Y, Min H, Zhao X, Zhang Y, et al. Sulforaphane mediates glutathione depletion via polymeric nanoparticles to restore cisplatin chemosensitivity. ACS Nano. 2019;13:13445–55. https://doi.org/10.1021/acsnano.9b07032.10.1021/acsnano.9b07032 ↗
17. Song W, Tang Z, Shen N, Yu H, Jia Y, Zhang D, et al. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. J Control Rel. 2016;231:94–102. https://doi.org/10.1016/j.jconrel.2016.02.039.10.1016/j.jconrel.2016.02.039 ↗
18. Ling X, Chen X, Riddell IA, Tao W, Wang J, Hollett G, et al. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. Nano Lett. 2018;18:4618–25. https://doi.org/10.1021/acs.nanolett.8b01924.10.1021/acs.nanolett.8b01924 ↗